Sperm Count Test Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technique (Microscopy, Chromatographic Immunoassay and Colorimetric Reaction, Smartphone-based, Others), By End User (Hospitals, Fertility Centers, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 3.13 Billion
CAGR (2026-2031)	7.05%
Fastest Growing Segment	Smartphone-based
Largest Market	North America
Market Size (2031)	USD 4.71 Billion

Market Overview

The Global Sperm Count Test Market will grow from USD 3.13 Billion in 2025 to USD 4.71 Billion by 2031 at a 7.05% CAGR. The Global Sperm Count Test Market comprises diagnostic solutions designed to analyze sperm concentration and quality for fertility assessment in both clinical and home-based settings. Market growth is fundamentally driven by the rising prevalence of male infertility and declining global sperm counts, which necessitate frequent and accessible screening options. According to the American Urological Association and the American Society for Reproductive Medicine, in 2024, male factor infertility was identified as a contributing cause in up to 60 percent of couples experiencing difficulty conceiving. This high prevalence, combined with heightened awareness of reproductive health issues, creates a sustained demand for accurate diagnostic modalities.

However, market expansion is significantly challenged by the prohibitive costs associated with advanced fertility testing and the lack of comprehensive insurance reimbursement in many regions. This financial burden often restricts patient access to essential diagnostic services, particularly in developing economies, thereby impeding the broader adoption of sperm count testing solutions despite the evident clinical need.

Key Market Drivers

The rising prevalence of male infertility and declining sperm quality are the primary engines propelling the Global Sperm Count Test Market. As environmental stressors and lifestyle changes increasingly impact reproductive health, the clinical urgency for frequent and precise semen analysis has intensified. This biological crisis is quantified by alarming downward trends in sperm parameters, necessitating robust diagnostic interventions. According to Igyxos Biotherapeutics, June 2024, global sperm counts have declined by more than 2.6 percent per year since 2020, a significant acceleration from the 1.2 percent annual decrease observed in previous decades. This rapid deterioration drives men to seek early screening, expanding the addressable market for both clinical and consumer-grade testing solutions. Furthermore, the sheer scale of the issue supports sustained market momentum; according to Ferring Pharmaceuticals, in 2024, infertility affects approximately one in six people worldwide, creating a vast patient pool requiring reliable diagnostic evaluation.

Concurrently, the surging demand for private at-home fertility testing kits is reshaping market delivery models. Men are increasingly choosing direct-to-consumer solutions that offer anonymity and convenience, bypassing traditional clinical settings. This shift is fueled by the destigmatization of male infertility and the integration of smartphone-based analysis technologies that make testing user-friendly. The rapid adoption of these remote diagnostic tools is evident in the operational growth of key industry players. According to Legacy, July 2024, the digital fertility clinic has analyzed more than 25,000 sperm samples to date, securing $7.5 million in new financing to meet this demand. This distinct preference for home-based collection methods is effectively decentralizing the market, allowing providers to reach untreated populations and fostering a new segment of proactive reproductive health management.

Download Free Sample Report

Key Market Challenges

The prohibitive cost associated with fertility diagnostics and the lack of comprehensive insurance reimbursement stands as a primary obstacle to the growth of the Global Sperm Count Test Market. While basic screenings may appear accessible, they are often the initial step in a broader, expensive medical journey that many patients cannot afford. In regions where healthcare coverage for reproductive issues is limited or non-existent, the financial burden falls entirely on the patient. This economic pressure creates a significant barrier to entry, causing individuals to delay or forego essential diagnostic procedures. As a result, the market struggles to penetrate developing economies and lower-income demographics where the clinical need is high but the ability to pay is low.

The magnitude of this financial deterrent is underscored by recent data from industry authorities. According to the American Society for Reproductive Medicine, in 2024, the average cost for a single cycle of fertility treatment ranged between $12,000 and $15,000. This substantial expense often discourages patients from even beginning the diagnostic process, fearing the cascading costs of potential treatment. Consequently, the demand for sperm count tests is artificially suppressed, as economic constraints force many couples to opt out of the reproductive healthcare system entirely.

Key Market Trends

The integration of Artificial Intelligence (AI) and Machine Learning (ML) is fundamentally altering the technological landscape of the Global Sperm Count Test Market by transitioning semen analysis from subjective manual evaluation to high-precision automated diagnostics. These algorithmic advancements are embedding clinical-grade accuracy into portable devices, allowing for the rapid assessment of sperm morphology and motility without the variability inherent in human observation. This technological leap is exemplified by recent breakthroughs in non-invasive imaging; according to The Nightly, August 2024, researchers at Monash University developed an AI-driven model capable of analyzing live sperm samples with 93 percent accuracy in seconds, significantly outperforming traditional time-consuming methods. By automating complex diagnostic criteria, these innovations are standardizing results across both home-based and clinical environments, thereby enhancing the reliability of fertility data.

Concurrently, the market is experiencing a decisive convergence with telehealth services, effectively transforming sperm count testing from a standalone diagnostic product into a gateway for comprehensive remote fertility care. This trend addresses the critical disconnect between initial screening and subsequent medical intervention, as digital platforms now seamlessly connect users with reproductive urologists immediately following test completion. This integrated care model is vital for capturing untreated populations; according to Posterity Health, June 2024, despite data suggesting that over 3 million men in the United States suffer from testosterone deficiency—a key fertility indicator—only 32 percent currently seek professional treatment due to access barriers. By embedding diagnostics within a broader virtual health ecosystem, companies are removing these hurdles, ensuring that abnormal test results trigger immediate, actionable medical pathways rather than leaving patients isolated.

Segmental Insights

Based on market analysis, the smartphone-based segment currently represents the fastest-growing category within the global sperm count test market. This rapid expansion is primarily driven by the increasing consumer preference for private, cost-effective, and immediate fertility assessments conducted in a home setting. The growth is further supported by the integration of mobile applications with optical attachments, which allows users to perform clinical-grade analysis using personal devices. Furthermore, clearances from regulatory bodies such as the US Food and Drug Administration for specific mobile-enabled testing kits have validated the accuracy of these solutions, significantly boosting consumer adoption and market penetration.

Regional Insights

North America maintains a leading position in the global sperm count test market, driven by the high prevalence of male infertility and a well-established healthcare infrastructure. The region benefits from a supportive regulatory environment, where the U.S. Food and Drug Administration (FDA) plays a crucial role in validating home-use diagnostic devices. Additionally, the concentrated presence of key manufacturers and growing public awareness regarding reproductive health further stimulate market activity. These factors, combined with accessible medical resources, ensure North America remains the primary contributor to global market revenue.

Recent Developments

• In June 2025, PS Fertility announced the successful closure of a $3.5 million Series A funding round to support the commercial launch and scaling of its new diagnostic product, PS Detect. This mail-order test was introduced to assess the presence of phosphatidylserine on the sperm surface, a critical biomarker for fertilization that standard semen analyses often overlook. The capital injection, led by Flourish Investments and other backers, was designated to accelerate the distribution of this testing kit, which aims to provide physicians and patients with deeper insights into male infertility causes beyond traditional count and motility metrics.
• In December 2024, Astorg completed the acquisition of Hamilton Thorne and the Reproductive Health business of Cook Medical to form a new global entity in the Assisted Reproductive Technology sector. This consolidation combined Hamilton Thorne’s expertise in precision instruments and software, including computer-assisted sperm analysis systems, with Cook Medical’s portfolio of fertility consumables. The transaction, which resulted in the delisting of Hamilton Thorne from the Toronto Stock Exchange, aimed to create a comprehensive provider of equipment and products to support fertility clinics and research laboratories worldwide in improving patient outcomes.
• In October 2024, ARC Fertility established a strategic partnership with Sapyen to integrate an at-home male fertility testing solution into its family-forming benefits packages. This collaboration allowed the company to offer employer-sponsored health plan members a private and convenient method to conduct clinical-grade semen analysis from their homes. The initiative was designed to address the significant role of male factors in infertility by removing barriers to testing, such as the need for clinic visits. By providing accessible diagnostic tools, the partnership aimed to facilitate early detection of fertility issues and support more effective treatment planning for couples.
• In June 2024, Contraline entered into a collaboration with the DNA Diagnostics Center to utilize the SpermCheck Vasectomy at-home test kit in the clinical trial of a new male contraceptive device. The study integrated this consumer sperm monitoring product into the protocol for ADAM, a hydrogel implant designed to block sperm transport in the vas deferens. This arrangement enabled trial participants to verify the efficacy of the contraceptive implant and monitor their sperm count status from the privacy of their homes. The partnership demonstrated the expanding utility of rapid sperm count tests in clinical research and the validation of novel reproductive health therapies.

Key Market Players

• DNA Diagnostics Center, Inc.
• BioMérieux SA
• Medical Electronic Systems
• Thermo Fisher Scientific Inc.
• CooperSurgical, Inc.
• Vitrolife Sweden AB
• Hamilton Thorne Inc.
• Artron Laboratories Inc.
• Fertility Focus Ltd.
• MICROPTIC S.L.

By Technique	By End User	By Region
Microscopy Chromatographic Immunoassay and Colorimetric Reaction Smartphone-based Others	Hospitals Fertility Centers Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Sperm Count Test Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Sperm Count Test Market, By Technique:

• Microscopy
• Chromatographic Immunoassay and Colorimetric Reaction
• Smartphone-based
• Others

• Sperm Count Test Market, By End User:

• Hospitals
• Fertility Centers
• Others

• Sperm Count Test Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE